Shangjin Li
Novo Nordisk
ImmunologyImmunotherapyCytokineAutoimmune diseaseImmunosuppressionType 1 diabetesDiabetes mellitusMedicineInterleukinImmune system
Publications 1
#1Philippe P. Pagni (Novo Nordisk)H-Index: 4
#2Chaplin Jay (Novo Nordisk)
Last. Shangjin Li (Novo Nordisk)
view all 16 authors...
Type 1 diabetes is an autoimmune disease in which insulin-secreting β-cells are destroyed, leading to a life-long dependency on exogenous insulin. There are no approved disease-modifying therapies available, and future immunotherapies would need to avoid generalized immune suppression. We developed a novel plasmid expressing preproinsulin2 and a combination of immune-modulatory cytokines (transforming growth factor-beta-1, interleukin [IL] 10 and IL-2) capable of near-complete prevention of auto...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.